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Diabetes mellitus is one of the major causes of morbidity and mortality worldwide.
Despite lack of scientific evidences to support its therapeutic efficacy, the use of herbal
supplements has significantly increased. Guar gum has a wide variety of non-food and
food uses as a stiffener in ice cream, yogurt, bakery, and soups; as a stabilizer for
cheeses, puddings, and cream; and as a meat binder. Therefore being safe, it was tried in
model type II diabetes induced by streptozotocin (STZ) in rats, compared to gliclazide.
Healthy Sprague Dawley male adult rats were randomly divided into 5 equal groups
namely A, B, C, D, and E (group A and B) were kept as normal control and diabetic
control. The other diabetic groups from group C to group E were treated as follow Gli-
clazide 4.5 mg/kg, Guar gum 200 mg/kg and Guar gum 200 mg/kg plus gliclazide 4.5 mg/kg
respectively for 14 consecutive days. Blood glucose, insulin, glycosylated hemoglobin
(HbA1c), superoxide dismutase (SOD), malondialdehyde (MDA), reduced glutathione
(GSH), lactate dehydrogenase (LDH), urea, insulin resistance, insulin sensitivity and b-
cell function were measured. Guar gum exerted antidiabetic activity nearly similar to
that of gliclazide as indicated by significant reduction of glucose, HBA1c, and insulin
resistance. Elevation of insulin and b-cell function was also observed. Guar gum and
gliclazide showed antioxidant activity as seen by significant reduction of MDA and LDH.
This was associated with marked elevation of GSH and SOD. Urea was also reduced after
Guar gum and gliclazide. Similar effects were also seen after combination of gliclazide
with Guar gum. It could be concluded that Guar gum could be used safely as an adjunct.com (M.R. Nasry).
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its associated complications by reducing the oxidative stress and urea level. Further
clinical studies are needed.
Copyright 2013, Beni-Suef University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction Themain goal of the present study is to use Guar gum aloneDiabetes mellitus is a complex, chronic disorder that results
from partial, complete or relative lack of insulin secretion by
pancreatic b-cells and/or impairment of insulin action
(Anderson et al., 1994). The crude prevalence rate of known
diabetes in Egypt in 2008 was 4.07%. It increased with age, to
reach 19.8% among female aged 50e59 (Naglaa & Ghada, 2010).
It is estimated that by the year 2030, Egyptwill have at least 8.6
million adults with diabetes (Shaw et al., 2010).
Diabetes mellitus is classified into Type I diabetes mellitus,
Type 2 diabetes mellitus, gestational diabetes mellitus
(Anderson et al., 1994; Sherwin, 2006), and other types of
diabetes mellitus. Other types of diabetes mellitus include
genetic defects of beta-cell function or defects of insulin ac-
tion. diseases of the exocrine pancreas, such as pancreatitis or
cystic fibrosis; dysfunction associated with other endo-
crinopathies (e.g., acromegaly); and pancreatic dysfunction
caused by drugs-chemicals such as glucocorticoids, phenytoin
and thiazides (Bennett, 1994; Vuksan et al., 2001).
Hyperglycemia promotes oxidative stress and hence gen-
eration of reactive oxygen species (ROS), which is known to
play a crucial role in the pathogenesis of diabetic nephropathy
(DN) (Pan et al., 2010) in which increased ROS production and
oxidative stress cause cell membrane damage, enzymes
inactivation, apoptosis, and endogenous antioxidant altered
gene expression (Swaminathan and Shah, 2008).
Management of hyperglycemia in most patients with Type
II DM should begin with lifestyle modification (diet and ac-
tivity) (Nathan et al., 2009). However, diets and exercise fail to
achieve glycemic control inmost patients thus pharmacologic
intervention with oral hypoglycemic agents is necessary. Gli-
clazide is an effective oral hypoglycemic agent which reduces
blood glucose levels in animal models of diabetes, healthy
volunteers as well as Type 2 diabetic patients (Holmes et al.,
1984; Matthews et al., 2007). Gliclazide is a second genera-
tion sulfonylurea which, like other oral hypoglycemic, is
indicated as an adjunct to diet and exercise in Type 2 diabetic
patients whose hyperglycemia cannot be controlled by diet
and exercise alone.
Herbal drugs are prescribed widely because of their effec-
tiveness, less side effects and relatively low cost (Venkatesh
et al., 2003). Guar gum is simple, non-ionic and best-
characterized branched polysaccharide extracted from Cya-
mopsis tetragonoloba seeds (Frias and Sgarbier, 1998).
Numerous studies supported that Guar gum lowers the post-
prandial glucose response when mixed into a variety of test
meals (Jenkins et al., 1977; Collier et al., 1986; Leclere et al.
1994). The supplementation of high carbohydrate diets with
Guar gum has been demonstrated to effectively enhance in-
sulin sensitivity in individuals with either NIDDM or IDDM
(Tagliaferro et al., 1985; Ebeling et al., 1988; Lalor et al., 1990).or in combination with gliclazide to increase its antidiabetic,
antioxidant activity and decrease its adverse effects in the
treatment of diabetes mellitus induced experimentally in rats
by STZ.2. Materials and methods
2.1. Materials
2.1.1. Animals
Sprague Dawley male adult rats weighing 150e200 g obtained
from National Research Center, Cairo, Egypt. Animals were
housed in plastic cages (28 cm  43 cm  18 cm) and were
maintained under conventional laboratory conditions of
temperature (20  5 C), with a regular 12-h light/12-h dark
cycle throughout the study. They were fed standard pellet
chow (El-Nasr chemical Co., Cairo, Egypt.) and were allowed
water ad libitum.
All experimental procedures were conducted in accordance
with ethical procedures and policies approved by the Ethics
Committee of Faculty of Pharmacy, Beni Suef University.
2.1.2. Drugs
a- Gliclazide
Gliclazide was provided as a gift from Amoun, Co. (EGYPT).
Gliclazide was suspended in 2% Tween 80, gum acacia 2% and
orally administered in a dose of 4.5 mg/kg (Habib et al., 2005).
b- Guar gum
Guar gum seeds available in powder form, were purchased
from local market. Guar gum was extracted with petroleum
ether (60e80 C) in a soxhlet apparatus for 72 h. After removal
of the solvent in under vaccum at 40 C, the residual extract
was collected. The petroleum ether extract obtained was
suspended in 2% tween 80, 2% gum acacia and given orally
(p.o.) in a dose of 200 mg/kg (Bhandari and Sharma, 1999).
2.2. Methods
2.2.1. Induction of experimental diabetes
After fasting for 18 h, diabetes was induced by intraperitoneal
injection of streptozotocin (Sigma, St. Louis, MO, USA) dis-
solved in 0.1 M cold sodium citrate buffer, pH 4.5, at a dose of
50 mg/kg (Hounsom et al., 1998). The animals were allowed to
drink 5% glucose solution overnight to overcome the drug
induced hypoglycemia (Hajduch et al., 1998). Diabetes was
confirmed by the presence of glucosuria using gluckotest
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Fig. 1 e Effect of two week daily dose administration of
gliclazide and Guar gum alone or in combination on serum
glucose level in streptozotocin-induced diabetic male rats.
*: Significantly different from the normal control group at
P< 0.05. a: Significantly different from the diabetic control
group at P< 0.05. b: Significantly different from gliclazide
treated group at P< 0.05. Glic[ Gliclazide G.G[ Guar gum.
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persistent hyperglycemia.
2.2.2. Experimental design
Group 1: Normal rats received citrate buffer and served as the
normal control.
Group 2: Diabetic control rats received STZ (50mg/kg, i.p.) and
served as the diabetic control.
Group 3: Diabetic rats received gliclazide (4.5 mg/kg, p.o.).
Group 4: Diabetic rats received Guar gum (200 mg/kg, p.o.).
Group 5: Diabetic rats received gliclazide (4.5 mg/kg, p.o.) and
Guar gum (200 mg/kg, p.o.).
At the end of the experiment rats were subjected to light
ether anaesthesia then blood were collected from the retro -
orbital venous plexus following the technique described by
Coccheto and Bjornsson (1983), using heparinized micro-
hematocrit capillary tubes intoWassermann tubes. Serumwas
separated by centrifugation at 3000 rpm for 10e15 min at room
temperature for the determination of serum glucose, insulin,
MDA, LDH and urea levels. For the, assessment of blood SOD
and GSH level blood samples were hemolyzed by addition of
cold distilled water. On the 35th day of the experiment, blood
samples of each rat were collected after decapitation, using
EDTA for the determination of glycosylated hemoglobin.
2.2.2.1. Determination of serum glucose and insulin levels.
Fasting serum glucose was estimated by glucose oxidase
method Trinder (1969).Insulin in samples were estimated
using Enzyme Linked Immunosorbent Assay (ELISA) (King
et al., 2002).
2.2.2.2. Determination of insulin resistance, insulin sensitivity
and b-cell function. Insulin resistance and b-cell function were
done using homeostasis model assessment (HOMA)
(Mattewes et al., 1985). Insulin sensitivitywas calculated using
quantitative insulin sensitivity check index (QISCKI) (Katz
et al., 2000).
2.2.2.3. Determination of glycosylated hemoglobin in blood.
Glycosylated hemoglobin level was determined according to
the method described by Trivelli et al. (1971), using glyco-
hemoglobin kit (TECO DIAGNOSTICS, U.S.A.).
2.2.2.4. Determination of serum malondialdehyde (MDA), su-
peroxide dismutase (SOD) and glutathione (GSH). Serum MDA
was estimated by the method of Mihara and Uchiyama (1978).
SOD activity wasmeasured based on the ability of the enzyme
to inhibit the autoxidation process of pyrogallol method of
Marklund and Marklund (1974). Glutathione was estimated by
the method of Beutler et al. (1963).
2.2.2.5. Determination of serum lactate dehydrogenase (LDH)
and blood urea nitrogen (BUN). Serum LDH level was deter-
mined according to the method of Weisshaar et al. (1975)
using LDH kit purchased from Randox Laboratories Ltd,
Crumlin, U.K. Serum urea was determined according to the
method of Tobacco et al. (1979) using the kit purchased from
Stanbio Laboratory, Texas, U.S.A.2.3. Statistical analysis
Data were expressed as the mean  standard error of the
mean (S.E.M); and comparison between the different treat-
ments was carried out using analysis of variance (ANOVA)
followed by TukeyeKramer multiple comparisons test.3. Results
3.1. Effect of two week daily dose administration of
gliclazide and Guar gum alone or in combination on serum
glucose and insulin levels in streptozotocin-induced diabetic
male rats
The results are graphically illustrated in Figs. 1 and 2. Strepto-
zotocin significantly increased serum glucose level and signif-
icantly decreased serum insulin level as compared to normal
control value. Gliclazide and Guar Gum significantly decreased
serum glucose level by 51.58% and 36.82 respectively of the
diabetic control value. Concurrent administration of gliclazide
and Guar gum significantly reduced serum glucose level and
significantly increased serum insulin level as compared to the
diabetic control value.
3.2. Effect of two week daily dose administration of
gliclazide and Guar gum alone or in combination on insulin
resistance insulin sensitivity and b-cell function in
streptozotocin-induced diabetic male rats
The results are graphically illustrated in Figs. 3e5. Therewas a
significant increase in insulin resistance and significant
decrease in insulin sensitivity and b-cell function as compared
to the corresponding normal control value.
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Fig. 2 e Effect of two week daily dose administration of
gliclazide and Guar gum alone or in combination on serum
insulin level in streptozotocin-induced diabetic male rats.
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Fig. 4 e Effect of two weeks daily dose administration of
gliclazide and Guar gum alone or in combination on insulin
sensitivity level of streptozotocin-induced diabetic male
rats.
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resistance level and significantly increased insulin sensitivity.
Similarly, Guar gum reduced insulin resistance. Concurrent
administration of gliclazide and Guar gum significantly
decreased insulin resistance.3.3. Effect of two weeks daily dose administration of
gliclazide and Guar gum alone or in combination on blood
glycosylated hamoglobin(HBA1c) level of streptozotocin-
induced diabetic male rats
The results are graphically illustrated in Fig. 6. Streptozotocin
significantly elevated blood HBA1c level as compared to the
corresponding normal control value. Gliclazide and Guar gum
significantly decreased blood HBA1c as compared to the cor-
responding diabetic control value. Concurrent administration
of gliclazide and Guar gum nearly normalized blood HBA1c.No
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Fig. 3 e Effect of two weeks daily dose administration of
gliclazide and Guar gum alone or in combination on insulin
resistance level of streptozotocin-induced diabetic male
rats.3.4. Effect of two weeks daily dose administration of
gliclazide and Guar gum alone or in combination on blood
SOD, serum MDA and blood GSH levels of streptozotocin-
induced diabetic male rats
The results are graphically illustrated in Figs. 7e9. Therewas a
significant increase in serum MDA and significant decrease
blood GSH and SOD during diabetes as compared to corre-
sponding control group. Gliclazide significantly increased
blood SOD and GSH levels and significantly decrease serum
MDA level as compared to the diabetic control value.Guar gum
did not show any significance in blood SOD level when
compared to the diabetic control. However, it significantly
decreased serum MDA level and significantly elevated blood
GSH as compared to the diabetic control value. Concurrent
administration of gliclazide and Guar gum showed signifi-
cantly decreased blood SOD level and serum MDA level and
significantly increased blood GSH level. It is to be noted thatNo
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Fig. 5 e Effect of two weeks daily dose administration of
gliclazide and Guar gum alone or in combination on b-cell
function level of streptozotocin-induced diabetic male rats.
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Fig. 6 e Effect of two week daily dose administration of
gliclazide and Guar gum alone or in combination on blood
HBA1c level in streptozotocin-induced diabetic male rats.
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Fig. 8 e Effect of two week daily dose administration of
gliclazide and Guar gum alone or in combination on serum
MDA level in streptozotocin-induced diabetic male rats.
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to gliclazide alone.
3.5. Effect of two weeks daily dose administration of
gliclazide and Guar gum alone or in combination on serum
LDH and urea levels of streptozotocin-induced diabetic male
rats
The results are graphically illustrated in Figs. 10 and 11.
Streptozotocin increased serum LDH level and serum urea
level compared to the corresponding normal control value.
Gliclazide and Guar gum significantly reduced serum LDH and
urea levels as compared to the diabetic control value. Guar
gum showed no significance difference on serum LDH level or
serum urea level as compared to gliclazide alone. Concurrent
administration of gliclazide and Guar gum significantly
reduced serum LDH and serum urea level as compared to the
diabetic control value. The effect of this combination on
serum LDH level was not better than gliclazide alone.60
80
%4. Discussion
In the present study, streptozotocin was chosen to induce
diabetes in rats because of its lower toxicity and higher b-cellNor
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Fig. 7 e Effect of two week daily dose administration of
gliclazide and Guar gum alone or in combination on blood
SOD level in streptozotocin-induced diabetic male rats.specificity relative to other diabetogens (Rakieten et al., 2003).
Findings of the present investigation revealed that STZ e
induced diabetes resulted in a significant increase in serum
glucose level and significant decrease in serum insulin level.
In addition, STZ caused elevation in glycosylated hemoglobin
(HBA1c) level.
The diabetogenic effects of STZ confirmed in this study is
in accordance with Bwititi et al. (2000) in STZ-diabetic rats and
Serradas et al. (1993) who reported that STZ in rats is associ-
ated with hyperglycemia. This diabetogenic effect could be
due to the destructive effect streptozotocin on pancreatic
islets.
The mechanism of decreased insulin secretion could be
attributed to the resultant hyperglycemia that induced ab-
normalities in insulin action and secretion (Rossetti et al.,
1987; Evans et al., 2003). Hyperglycemia is also associated
with the consequences of hyperinsulinemia, insulin resis-
tance, and glucose intolerance in diabetes (Kaur et al., 2002).No
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Fig. 9 e Effect of two week daily dose administration of
gliclazide and Guar gum alone or in combination on blood
GSH level in streptozotocin-induced diabetic male rats.
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Fig. 10 e Effect of two week daily dose administration of
gliclazide and Guar gum alone or in combination on serum
LDH level in streptozotocineinduced diabetic male rats.
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the diabetic group, is in accordance with Vijayaraghavan et al.
(2012) who reported that streptozotocin induced diabetic rats
showed a decrease in the hemoglobin level and a concomitant
increase in HbA1c. This could be due to excessive glycosyla-
tion of a number of proteins including hemoglobin (Gloria-
Botthini et al., 2000; Sampson et al., 2002). Furthermore, STZ
significantly increased oxidative stress biomarkers as indi-
cated by significant increase in serum MDA level and signifi-
cant decrease in blood SOD and blood GSH levels. This
observed increase in oxidative stress in STZ e induced dia-
betic rats is in agreement with the findings of many authors,
Kinalski et al. (2000) who reported a significant elevation in
MDA concentration in serum, liver and uterus of STZ diabetic
female rats. In addition Zadeh et al. (1997), Sundaram et al.
(1996); Kim et al. (2009) showed that thiobarbituric acid reac-
tive substances (TBARS) increased and GSH content decreased
in the liver of STZ-induced diabetic rats.
During diabetic state, increased generation of ROS occur
and cause an imbalance between the oxidant and antioxidant
status (Noda et al., 2000). Sustained hyperglycemia has been
identified as a principlemediator of increased reactive oxygen
species generation in diabetes (Santakumari et al., 2003). ThisNo
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Fig. 11 e Effect of two week daily dose administration of
gliclazide and Guar gum alone or in combination on serum
urea level in streptozotocineinduced diabetic male rats.might be the result of suppression of b-cell proliferation and
inhibition of insulin gene transcription (Kaneto et al., 1999;
Robertson et al., 2003) that caused impairment of insulin
release.Moreover,STZ caused elevation in serum lactate de-
hydrogenase (LDH). The observed activity in LDH in the dia-
betic rats could be attributed to the excessive accumulation of
pyruvate, which is converted to lactate for which LDH is
needed (Chang and Schneider, 1972), as LDH is a cytosolic
enzyme that catalyzes the conversion of pyruvate to lactate in
anaerobic glycolysis, which is subsequently converted to
glucose in gluconeogenic flux. This explanation is in accor-
dance with Ainscow et al., 2000 who observed an increase in
LDH activity due to the impairment in glucose-stimulated
insulin secretion.
In the present study the elevated serum urea levels in the
STZ diabetic rats, is in accordance with Almadal et al. (1986)
who reported that diabetic rats produce two times as much
urea that is produced by normal rats. The mechanism of
increased serum urea level in STZ induced diabetes could be
attributed to increased protein catabolism and renal
dysfunction (Vijayaraghavan et al., 2012). This damage to the
renal cells ismainly due to glucosemediated osmotic diuresis,
reactive oxygen species and glucose overload.
Data of the current study showed that daily dose admin-
istration of gliclazide for 14 days reduced hyperglycemia in
STZ-induced diabetic rats. This is evidenced by significant
reduction in serum glucose level and serum HBA1c level as
well as significant rise in serum insulin level. The observed
hypoglycemic action of gliclazide in this study is in agreement
with Pulido et al. (1997) who reported that gliclazide has a
glucose lowering effect in STZ e induced diabetic rats and
with the work of Zhao et al. (2002) who showed that gliclazide
increase blood insulin and decreases blood glucose in STZ
diabetic rats. Antidiabetic sulfonylureas are thought to stim-
ulate insulin secretion solely by inhibiting their high-affinity
ATP-sensitive potassium (K (ATP)) channel receptors at the
plasma membrane of beta-cells. This normally occurs during
glucose stimulation, where ATP inhibition of plasma mem-
brane K (ATP) channels leads to voltage activation of L-type
calcium channels for rapidly switching on and off calcium
influx, governing the duration of insulin secretion (Geng et al.,
2007).
Data of the present investigation showed that gliclazide
reduced insulin resistance and improved insulin sensitivity.
This result is in accordance with Bak et al. (1989) who reported
that gliclazide increased insulin sensitivity in skeletal muscle.
Moreover, Tsiani et al. (1995) reported an increase in glucose
utilization in muscles and adipose tissues and increase in
glucose uptake by rat and mouse skeletal muscle cells. Also
Ananya et al. (2011) reported that gliclazide increases pe-
ripheral glucose utilization, decrease hepatic gluconeogenesis
and may increase the number and sensitivity of insulin re-
ceptors . This may explain the effect of gliclazide in elevated
insulin sensitivity and lowered insulin resistance.
Oral administration of gliclazide to diabetic rats signifi-
cantly decreased the level of glycosylated hemoglobin, this
result is in accordance with Campbell et al. (1982). The
observed decrease in HbA1c level is probably due to improved
glycemic control. Furthermore, gliclazide exerted antioxidant
effects where it reduced serum MDA and elevated both SOD
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who reported that treatment with gliclazide prevented the
increase level of lipid peroxidation markers in plasma and
pancreas of diabetic rats. Also Onozato et al., 2004 and Alper
et al., 2005 reported that gliclazide reduced oxidative stress
in liver and kidney tissues of diabetic rats This observed
antioxidant effects of gliclazide could be attributed to the
aminoazabicyclo-octyl ring grafted onto its sulfonylurea core
(Ziegler and Drouin, 1994). Also Agnieszka et al. (2008) re-
ported that gliclazide may diminish the risk of hyperglycemia
driven oxidative stress and diabetic complications, possibly
due to its direct action as a free radical scavenger (Jennings,
2000).
The present study showed that gliclazide significantly
decreased LDH level. This result supported by Prasath and
Subramanian (2011) who reported that oral administration
of gliclazide to diabetic groups of rats showed a significant
reduction in the LDH activity. This is probably due to the
regulation of NADþ/NADH ratio by the oxidation of glucose. In
addition, there was significant decrease in serum urea level
after administration of gliclazide. This could be due to hypo-
glycemic and antioxidant effect of gliclazide (Vijayaraghavan
et al., 2012).
Data of the current study revealed that administration of
Guar gum for 14 consecutive days improved hyperglycemia in
STZ-induced diabetic rats as evidenced by significant reduc-
tion in serum glucose level and significant rise in serum in-
sulin level. In addition, Guar gum lowered insulin resistance
and improved insulin sensitivity as well as b-cell function.
The hypoglycemic effect of Guar gum in this study is in
agreement with Bhandari and Sharma (1999) who reported
that the oral administration of petroleum ether extract
significantly decreased blood glucose. This antihyperglycemic
action of Guar gum could be related to the ability of its fiber to
produce high viscosity at low concentration in the gut lumen,
(Lecer et al., 1994; Edwards, 2003), as these fibers aremolecules
that hold water and have the property of forming colloidal
gels. This decreases the association of food with the intestinal
mucosa and the enzymatic digestion rate, consequently
decreasing the intestinal absorption of monosaccharides and
disaccharides (Wilson et al., 1998) by delaying gastric
emptying or by interaction with digestive enzymes of the in-
testine (Nandini et al., 2003).
The improvement in insulin action following Guar gum
supplementation is in agreement with David et al. (1997) who
showed that elevated insulin mediated by increased periph-
eral tissue insulin sensitivity. Also Tagliaferro et al. (1985);
Ebeling et al. (1988) and Lalor et al. (1990), reported that the
supplementation of high carbohydrate diets with Guar gum
has been demonstrated to effectively enhance insulin sensi-
tivity. A possible mechanism by which the guar diet could
improve insulin sensitivity in the STZ diabetic rats is the in-
hibition of urinary glucose loss resulting in a suppression of
the hyperphagia.
As insulin resistance develops when both insulin secretion
is reduced and plasma glucose levels are elevated (David et al.,
1997), so the lowering effect of Guar gum on insulin resistance
in the present study may be attributed to this concept. Also
Lang (1991) reported that the detrimental actions of hyper-
glycemia are likely to be directed towards insulin-sensitiveglucose transport and metabolism within skeletal muscle
because the majority of the infused glucose load during
hyperinsulinemia is cleared from the plasma by skeletal
muscle (Beck-Nielsen et al., 1992). Moreover Guar gum in the
present study showed antioxidant properties as it signifi-
cantly decreased MDA level and increased GSH levels. This is
in accordancewith Trommer andNeubert (2005) who reported
that Guar gum has lipid protective effects, also Albertini et al.
(2000) reported lipid peroxidation reducing effects of poly-
saccharides such as Guar gum. This effect seems to be due to
the chelation of transition metal ions. This chelation can lead
to antioxidant effects (Sipos et al., 2003).
In thepresent study, therewas significant decrease in serum
LDH level after treatment with Guar gum. As mentioned before
that LDH is released into the blood stream following loss of
membrane integrity resulting from either apoptosis or necrosis.
LDH activity, therefore, can be used as an indicator of cell
membrane integrity (Haslam et al., 2000; Wolterbeek and Van
deer Meer, 2005), so the antioxidant effect of Guar gum could
be the main reason for significant decrease in LDH activity.
Guar gum significantly decreased serum urea level, this
result is in accordance with Bhandari and Sharma (1999) who
reported that the petroleum extract of Guar gum significantly
decreased blood urea levels and decreased the serum proteins
and albumin levels, which is a significant finding as it in-
dicates reversal in pathological events occurring secondary to
diabetes mellitus. Also Nandini et al. (2003) reported that Guar
gum effective in controlling renal enlargement, which occurs
during early stages of diabetes.
It could be concluded that Guar gum decreased STZ-
induced hyperglycemia and ameliorated oxidative stress,
similar to gliclazide alone. Its antidiabetic activity may be
related to increased insulin secretion and antioxidant activity.r e f e r e n c e s
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